Showing results (31-40 of 51) with videos related to
Sort By:
Pageof 6
Journal of Molecular Biology|March 25, 2000
Plasminogen activator inhibitor 1. Structure of the native serpin, comparison to its other conformers and implications for serpin inactivationH Nar, M Bauer, J M Stassen, et al.Alimentary Pharmacology & Therapeutics|August 10, 2016
Prognostic factors for long-term infliximab treatment in Crohn's disease patients: a 20-year single centre experienceT Billiet, I Cleynen, V Ballet, et al.Journal of Thrombosis and Haemostasis : JTH|August 2, 2007
Comparative evaluation of stable TAFIa variants: importance of alpha-helix 9 and beta-sheet 11 for TAFIa (in)stabilityE Ceresa, M De Maeyer, A Jonckheer, et al.Journal of Thrombosis and Haemostasis : JTH|April 22, 2004
Migration of the activation peptide of thrombin-activatable fibrinolysis inhibitor (TAFI) during SDS-polyacrylamide gel electrophoresisA H C Guimarães, M M Barrett-Bergshoeff, A Gils, et al.Journal of Thrombosis and Haemostasis : JTH|December 21, 2013
Identification of a novel, nanobody-induced, mechanism of TAFI inactivation and its in vivo applicationM L V Hendrickx, M Zatloukalova, G Hassanzadeh-Ghassabeh, et al.Journal of Thrombosis and Haemostasis : JTH|December 20, 2005
Modulation of TAFI function through different pathways--implications for the development of TAFI inhibitorsA Gils, E Ceresa, A M Macovei, et al.New Biotechnology|February 18, 2015
Ara h 1 protein-antibody dissociation study: evidence for binding inhomogeneities on a molecular scaleE Pérez-Ruiz, D Spasic, A Gils, et al.The British Journal of Dermatology|April 21, 2019
Clinical response correlates with 4-week postinjection ustekinumab concentrations in patients with moderate-to-severe psoriasisN Van den Berghe, E De Keyser, R Soenen, et al.Thrombosis and Haemostasis|May 25, 2001
Elucidation of the binding regions of PAI-1 neutralizing antibodies using chimeric variants of human and rat PAI-1A P Bijnens, T H Ngo, A Gils, et al.Alimentary Pharmacology & Therapeutics|October 14, 2017
Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseasesN Mitrev, N Vande Casteele, C H Seow, et al.Pageof 6